Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Wolfe Research analyst Andy Chen downgraded the rating for Blueprint Medicines Corporation (NASDAQ:BPMC) from Outperform to Peer Perform. Blueprint Medicines shares closed at $127.79 on Monday. See how other analysts view this stock.
- Jefferies analyst Chris LaFemina downgraded Rio Tinto Group (NYSE:RIO) from Buy to Hold. …
Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Wolfe Research analyst Andy Chen downgraded the rating for Blueprint Medicines Corporation (NASDAQ:BPMC) from Outperform to Peer Perform. Blueprint Medicines shares closed at $127.79 on Monday. See how other analysts view this stock.
- Jefferies analyst Chris LaFemina downgraded Rio Tinto Group (NYSE:RIO) from Buy to Hold. …
Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Wolfe Research analyst Andy Chen downgraded the rating for Blueprint Medicines Corporation (NASDAQ:BPMC) from Outperform to Peer Perform. Blueprint Medicines shares closed at $127.79 on Monday. See how other analysts view this stock.
Jefferies analyst Chris LaFemina downgraded Rio Tinto Group (NYSE:RIO) from Buy to Hold. …Full story available on Benzinga.com Read MoreASML, BMBL, BPMC, MTAL, News, RIO, Top Downgrades, Downgrades, Markets, Analyst Ratings, Trading Ideas, ASML, USN070591862, RIO, US7672041008, BPMC, BMBL, MTAL, News, Downgrades, Markets, Analyst Ratings, Trading Ideas, Benzinga Markets
